Anthropic Launches Claude Science Platform and Plans Its Own Drug Development
Anthropic announces Claude Science, a new AI workbench designed to help researchers by consolidating fragmented tools and datasets into a single environment. The platform also generates figures and visuals, aiming to streamline scientific workflows. Anthropic touts a long list of biotech and pharmaceutical customers already using Claude and frames the launch as a step toward dramatically accelerating scientific discovery and healthcare interventions.
In a notable shift, Anthropic reveals plans to develop drugs of its own, focusing on treatments for neglected diseases. Head of life sciences Eric Kauderer-Abrams leads the effort, positioning the company as one of the first major frontier AI firms to directly pursue drug development rather than just selling tools to others. The strategy puts Anthropic in the unusual position of competing with some of the same pharmaceutical companies it serves as a software provider.
The announcement places Anthropic in a broader AI drug race alongside companies like Insilico and Google DeepMind spinout Isomorphic Labs. While OpenAI, Amazon, and Google continue building their own life sciences platforms, the AI drug boom still faces significant hurdles before treatments reach patients. Anthropic's direct entry into drug development marks one of the most aggressive moves by an AI company into the pharmaceutical space to date.